To confirm the significance of ZDHHC5 in the prognosis of LUAD, we performed OS analysis of ZDHHC5 in 17 independent cohorts. The survival analysis results of ZDHHC5 in these 17 study cohorts was moderately heterogeneous (I2 = 45%). As shown in Figure 2G, the HR of ZDHHC5 corrected by meta-analysis was 1.19 (P < 0.01), which indicated ZDHHC5 was associated with an unfavorable prognosis in LUAD. We also performed survival analysis of ZDHHC5 in 3 molecular subtypes of LUAD (Figure 2H). In the overall survival, high expression of ZDHHC5 only showed lower survival probability in the PP (Proximal-proliferative, formerly magnoid) subgroup (P < 0.05), whereas the PI (Proximal-inflammatory, formerly squamoid) and TRU (Terminal respiratory unit, formerly bronchioid) subgroup did not (P > 0.05). However, the Kaplan-Meier curves of disease-free survival indicated ZDHHC5 expression was not associated with disease-free survival in the 3 subtypes (P > 0.05).
